Shanghai Novamab Biopharmaceuticals Co. Ltd. (Novamab), located in Shanghai International Medical Park (Pudong New Area, Shanghai), is a clinical stage company which is focused on the development of innovative VHH antibody drugs, primarily for the multi-billion dollar autoimmune and inflammatory disease markets. Our mission is to develop life-changing therapeutics for patients, through innovative variable domain of the heavy chain of heavy-chain antibody（VHH）drug research and development and aim to improve efficacy and convenience 

Novamab currently has around 65 full time employees, as one of the pioneers in VHH antibody development worldwide, we take pride in having a highly differentiated and innovative product pipeline targeting high-potential markets like asthma, chronic obstructive pulmonary disease (COPD), and IBD. Our focus is on creating unique treatment solutions that address significant clinical challenges. The most advanced is our inhaled IL-4R project, which has entered Phase II clinical trials, while our inhaled TSLP project is about to begin Phase IB proof-of-concept studies. Additionally, we are actively developing several bispecific and oral VHH antibody products aimed at treating inflammatory bowel disease (IBD).